While the search continues for the Fountain of Youth, researchers may have found the body's "fountain of aging": the brain region known as the hypothalamus.
[More]
For women with abdominal pain or vaginal bleeding during early pregnancy, patient history and clinical examination alone are insufficient to indicate or eliminate the possibility of ectopic pregnancy, while transvaginal sonography appears to be the single best diagnostic method for evaluating suspected ectopic pregnancy, according to an analysis of previous studies reported in the April 24 issue of JAMA.
[More]
Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the proliferation, or growth in the number of cells, of triple-negative breast cancer cells more effectively than cells from luminal types of the disease.
[More]
Neurosurgeons at the University of Texas-Houston and Children's Memorial Hermann Hospital (Houston, Texas) report on the success they achieved when they removed a hypothalamic hamartoma from a 10-year-old girl to combat hyperphagia (excessive appetite and compulsive overeating) and consequent unhealthy weight gain.
[More]
Neurocrine Biosciences, Inc. today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated.
[More]
FSH and LH are two important hormones which regulate the processes of puberty and maturation. These hormones are secreted by the pituitary gland and are transported in the blood to the genitalia, where they regulate maturation.
[More]
A high body mass index has no significant impact on parameters of sperm quality, although it does lower serum levels of testosterone, luteinizing hormone, and prolactin, say researchers.
[More]
A single progesterone measurement may be useful for predicting nonviable pregnancies in women with pain or bleeding when an ultrasound investigation proves to be inconclusive, say researchers.
[More]
Findings published in Annals of Neurology suggest that assisted reproduction technology treatment increases multiple sclerosis disease activity.
[More]
Treatment with a gonadotropin-releasing hormone agonist may reduce the risk for chemotherapy-induced amenorrhea, research shows.
[More]
Kisspeptin neurons appear to play a role in hypogonadotropic anovulation caused by excessive levels of prolactin, research shows.
[More]
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has selected three promising Uniformed Services University of the Health Sciences (USU) doctoral students to receive fellowships for the 2012-13 academic year. The program, established in 1988, includes two Henry M. Jackson Fellowships and one Val G. Hemming Fellowship. Each fellow receives a stipend and travel support.
[More]
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced that the first patient has been enrolled in an open-label phase III study to investigate the efficacy, safety, and pharmacokinetics of the sustained release triptorelin pamoate 22.5 mg 6-month-formulation in children with central precocious puberty (CPP), a rare disease.
[More]
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
[More]
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.
[More]
Poor perinatal outcome after the maternal perception of reduced fetal movement is linked to factors associated with placental dysfunction, say experts.
[More]
In vitro fertilisation (IVF) is linked to an increased rate of relapse among women with multiple sclerosis (MS), suggests a small study published online in the Journal of Neurology Neurosurgery and Psychiatry.
[More]
Abbott, in cooperation with Neurocrine Biosciences, Inc., today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis.
[More]
In an effort to provide clarity to the confusion surrounding the human chorionic gonadotropin (hCG) diet, The Hormone Foundation, the public education affiliate of The Endocrine Society, today published, "Myth vs. Fact: The Human Chorionic Gonadotropin (hCG) Diet."
[More]
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
[More]